RESEARCH MONOGRAPH · KDC-MN-023

Pitolisant

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

74/100

H3 inverse agonist with elegant mechanism and approval status. The histamine angle on wakefulness is real

Pitolisant (Wakix) is the most interesting eugeroic of the recent generation because it works through a mechanism that nobody else commercially exploits. H3 histamine receptor inverse agonism. The Schwartz lab at INSERM developed it (Jean-Charles Schwartz himself basically invented H3 pharmacology over decades), Bioprojet brought it through European development, and FDA approval for narcolepsy came in 2019 in the US.

The mechanism is genuinely elegant once you understand the H3 system. H3 receptors are presynaptic autoreceptors on histaminergic neurons, primarily in the tuberomammillary nucleus, where they restrain histamine release through negative feedback. When you block them with an antagonist (or, better, invert their constitutive activity with an inverse agonist), you remove the brake on histaminergic tone and you get sustained release of histamine through the cortex. Since histaminergic neurotransmission is one of the key wakefulness systems, this produces meaningful eugeroic effects without touching the dopamine or norepinephrine systems directly.

That mechanistic distinction matters because pitolisant doesn't have stimulant-class abuse liability. The Drug Enforcement Administration explicitly declined to schedule it after reviewing the clinical and abuse-potential data. The pharmacology is just different from the catecholamine-acting stimulants; it's the first time you've gotten a wakefulness drug to FDA approval through histamine pathway pharmacology.

Clinical evidence is solid. The HARMONY trials for narcolepsy showed effect sizes on the Epworth Sleepiness Scale and cataplexy frequency that compare favorably with modafinil-class drugs, and the safety profile in the clinical trials was reasonable. There are additional approved indications in Europe for hypersomnia and emerging research interest in attention disorders.

What we like is the proof-of-concept that wakefulness pharmacology has more than one tractable mechanism. The H3 receptor system was kind of an afterthought in CNS pharmacology for years (because the antihistamine market focused entirely on H1 and H2), and pitolisant has reopened that pharmacological landscape.

Sourcing for research is challenging because pitolisant is on-patent and the API supplier base is narrow. Quality material exists but vendor verification matters. HPLC and mass spec are standard requirements.

Genuinely interesting compound. Clean mechanism. Established clinical workhorse with novel pharmacology.

Evidence: 85
Mechanism: 88
Reliability: 82
Safety: 80
Sourcing: 55
Value: 45
Signal: 80
Staying power: 80

Plain-language summary Intrigue 76 / 100

Pitolisant, sold as Wakix, is a wakefulness-promoting medication that works through histamine receptors rather than dopamine. By blocking the H3 histamine autoreceptor (which normally puts a brake on histamine release), it increases brain histamine. FDA-approved for narcolepsy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

H3 histamine receptor inverse agonist

An FDA-approved selective H3 receptor inverse agonist for narcolepsy with cataplexy that elevates histamine and other monoamines through autoreceptor blockade.

Abstract

Pitolisant (Wakix, Ozawade; BF2.649; CAS 362665-56-3; molecular formula C17H26ClNO; molecular weight 295.85) is a selective H3 histamine receptor inverse agonist approved by the FDA in August 2019 for excessive daytime sleepiness in narcolepsy with or without cataplexy, and approved by the EMA earlier (2016) for the same indication. The compound was developed at Bioprojet Pharma in France through a structure-activity program targeting the H3 autoreceptor that controls histamine release in the tuberomammillary nucleus. The H3 receptor is a presynaptic Gi-coupled receptor; blockade lifts the negative feedback restraint on histamine release, elevating histamine in cortical and limbic regions. Downstream effects include increases in noradrenaline, dopamine, and acetylcholine release in cortical regions, with concurrent attenuation of histaminergic suppression of wakefulness. Pharmacokinetics: plasma half-life 10 to 12 hours; oral bioavailability greater than 90 percent; metabolism is hepatic via CYP2D6 (primary) and CYP3A4 (secondary); active metabolites contribute modestly to overall pharmacology. The clinical program demonstrated improvements in wakefulness measures (MWT, ESS) and reduction in cataplexy frequency in narcolepsy patients, with effect sizes comparable to modafinil and superior to placebo. The studied dose range titrated from approximately 8.9 mg to 35.6 mg. Not scheduled in most jurisdictions. Cardiovascular safety includes a QT prolongation signal that requires baseline ECG and dose-related monitoring. Drug-drug interactions are clinically relevant through CYP2D6 polymorphisms and concurrent CYP2D6 inhibitor or CYP3A4 inducer use.

Mechanism of action

Selective H3 inverse agonist; blocks histamine autoreceptor to elevate histamine release in cortex. Secondary increases in noradrenaline, dopamine, and acetylcholine.

Reported research dose ranges

Clinical trials studied a titrated range of approximately 8.9 to 35.6 mg.

References

Lin JS, et al. An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008.
Dauvilliers Y, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol 2013.
Szakacs Z, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-023

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Pitolisant

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs